Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada)
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.503
https://www.valueinhealthjournal.com/article/S1098-3015(13)02408-X/fulltext
Title :
Cost-Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients with Advanced ALK Positive Non-Small Cell Lung Cancer in a Publicly Funded System (Ontario, Canada)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02408-X&doi=10.1016/j.jval.2013.08.503
First page :
A410
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
484